Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00589667 · OUTCOME

Median Overall Survival

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC) · Source last updated 2014-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
2 years

What was measured

To determine the median overall survival for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma treated with pemetrexed and gemcitabine.

Analysis population: There were 25 assessable patients as described in the protocol.

Groups in this outcome

Pemetrexed Plus Gemcitabine

Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pemetrexed Plus Gemcitabine25

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pemetrexed Plus Gemcitabine8.8Not reported1.930.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.9
        upper Limit
        30.9
        value
        8.8
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
To determine the median overall survival for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma treated with pemetrexed and gemcitabine.
dispersion Type
Full Range
groups
  1. description
    Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
    id
    OG000
    title
    Pemetrexed Plus Gemcitabine
param Type
MEDIAN
population Description
There were 25 assessable patients as described in the protocol.
reporting Status
POSTED
time Frame
2 years
title
Median Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice